The Morning Journal (Lorain, OH)

Coronaviru­s vaccine test opens with 1st doses

- By Lauran Neergaard and Carla K. Johnson

SEATTLE » U.S. researcher­s gave the first shots in a first test of an experiment­al coronaviru­s vaccine Monday, leading off a worldwide hunt for protection even as the pandemic surges.

With careful jabs in the arms of four healthy volunteers, scientists at the Kaiser Permanente Washington Research Institute in Seattle began an anxiously awaited first-stage study of a potential COVID-19 vaccine developed in record time after the new virus exploded out of China and fanned out across the globe.

“We’re team coronaviru­s now,” Kaiser Permanente study leader Dr. Lisa Jackson said on the eve of the experiment. “Everyone wants to do what they can in this emergency.”

The Associated Press observed as the study’s first participan­t, an operations manager at a small tech company, received the injection in an exam room.

“We all feel so helpless. This is an amazing opportunit­y for me to do something,” Jennifer Haller, 43, of Seattle said before getting vaccinated. Her two teenagers “think it’s cool” that she’s taking part in the study.

After the injection, she left the exam room with a big smile: “I’m feeling great.”

Three others were next in line for a test that will ultimately give 45 volunteers two doses, a month apart. Neal Browning, 46, of Bothell, Washington, is a Microsoft network engineer who says his young daughters are proud he volunteere­d.

“Every parent wants their children to look up to them,” he said. But he’s told them not to brag to their friends. “It’s other people, too. It’s not just Dad out there.”

Monday’s milestone marked just the beginning of a series of studies in people needed to prove whether the shots are safe and could work. Even if the research goes well, a vaccine would not be available for widespread use for 12 to 18 months, said Dr. Anthony Fauci of the U.S. National Institutes of Health.

At a news conference, President Donald Trump praised how quickly the research had progressed. Fauci noted that 65 days have passed since Chinese scientists shared the virus’ genetic sequence. He said he believed that was a record for developing a vaccine to test.

This vaccine candidate, codenamed mRNA-1273, was developed by the NIH and Massachuse­tts-based biotechnol­ogy company Moderna Inc. There’s no chance participan­ts could get infected because the shots do not contain the coronaviru­s itself.

It’s not the only potential vaccine in the pipeline. Dozens of research groups around the world are racing to create a vaccine against COVID-19. Another candidate, made by Inovio Pharmaceut­icals,

is expected to begin its own safety study next month in the U.S., China and South Korea.

The Seattle experiment got underway days after the World Health Organizati­on declared the new virus outbreak a pandemic because of its rapid global spread, which has infected more than 169,000 people and killed more than 6,500.

COVID-19 has upended the world’s social and economic fabric since China first identified the virus in January, with broad regions shuttering schools and businesses, restrictin­g travel, canceling entertainm­ent and sporting events, and encouragin­g people to stay away from each other.

Starting what scientists call a first-in-humans study is a momentous occasion for scientists, but Jackson described her team’s mood as “subdued.” They’ve been working around-the-clock readying the research in a part of the U.S. struck early and hard by the virus.

 ?? TED S. WARREN — THE ASSOCIATED PRESS ?? A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronaviru­s, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle.
TED S. WARREN — THE ASSOCIATED PRESS A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronaviru­s, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle.

Newspapers in English

Newspapers from United States